An official website of the United States government.

This is not the current EPA website. To navigate to the current EPA website, please go to www.epa.gov. This website is historical material reflecting the EPA website as it existed on January 19, 2021. This website is no longer updated and links to external websites and some internal pages may not work. More information »

Updated Data on TSCA CBI Reviews

For Release: April 10, 2020

On April 10, 2020, EPA published the quarterly update of the Toxic Substances Control Act (TSCA) confidential business information (CBI) review statistics. This data summarizes the number of CBI cases under review and results of completed reviews through March 1, 2020. In addition, a spreadsheet showing the details of completed TSCA CBI determinations through March 1, 2020 is available.

Making this information publicly available continues to demonstrate the agency’s commitment to transparency while fulfilling its responsibilities under the Lautenberg Act amendments to TSCA. EPA has established numerous new processes, systems, and procedures to enable submitters to provide the information required when making confidentiality claims and to facilitate EPA's review, and where applicable, determinations on these claims. The statistics updated today show EPA's progress toward meeting these requirements.

View the statistics and access the updated data.

Background

In December 2019, EPA first released information and statistics on completed TSCA CBI determinations and reviews. The agency committed to updating this information quarterly.

Under TSCA, EPA must review and make determinations for certain confidential business information (CBI) claims. Specifically, TSCA section 14(g)(1) requires that EPA, within 90 days of receipt of the claim:

  • review and make determinations on confidential business information (CBI) claims for chemical identity after the chemical substance has been offered for commercial distribution; and
  • review and make determinations on a representative subset of at least 25% of other CBI claims that are not exempt from substantiation and review.